Correlations of platelet-derived microparticles with thromboxane B2, platelet-activating factor, endothelin-1, and neutrophil to lymphocyte ratio in patients with coronary intermediate lesions

Biomarkers

Volumn 19, Issue 8, 2014, Pages 684-692

  Chou, Yuan I Scarlet ^a   Kong, Jinge ^b   Song, Rui ^a   Yan, Lulu ^a   Zheng, Lemin ^c   Zhang, Yongzhen ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Coronary heart disease; Coronary intermediate lesion; Fractional flow reserve; Intravenous ultrasound; Platelet derived microparticles

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN 1; IOHEXOL; IOPROMIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY INTERMEDIATE LESION; ECHOGRAPHY; ENDOTHELIUM INJURY; FEMALE; FRACTIONAL FLOW RESERVE; HUMAN; INTRAVENOUS ULTRASOUND; ISCHEMIC HEART DISEASE; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET MICROPARTICLE; THROMBOCYTE ACTIVATION; CORONARY ARTERY DISEASE; CYTOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOCYTE;

AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; ENDOTHELIN-1; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PLATELET ACTIVATING FACTOR; PLATELET ACTIVATION; THROMBOXANE B2;

EID: 84912074390     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.981293     Document Type: Article

References (40)

1. Arbel Y, Finkelstein A, Halkin A, et al. (2012). Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis 225: 456-60.
2. Azab B, Zaher M, Weiserbs KF, et al. (2010). Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol 106:470-6.
3. Azzam H, Zagloul M. (2009). Elevated platelet microparticle levels in valvular atrial fibrillation. Hematology 14:357-60.
4. Bhat T, Teli S, Rijal J, et al. (2013). Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 11: 55-9.
5. Bourque SL, Davidge ST, Adams MA. (2011). The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol 300:R1288-95.
6. Furman MI, Gore JM, Anderson FA, et al. (2004). Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 147:42-8.
7. Gambim MH, do Carmo Ade O, Marti L, et al. (2007). Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction. Crit Care 11:R107.
8. Inoue T, Komoda H, Kotooka N, et al. (2008). Increased circulating platelet-derived microparticles are associated with stent-induced vascular inflammation. Atherosclerosis 196:469-76.
9. Italiano Jr JE, Mairuhu AT, Flaumenhaft R. (2010). Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 17:578-84.
10. Iwamoto S, Kawasaki T, Kambayashi J, et al. (1996). Platelet microparticles: a carrier of platelet-activating factor? Biochem Biophys Res Commun 218:940-4
11. Katopodis JN, Kolodny L, Jy W, et al. (1997). Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol. 54:95-101.
12. Kounis NG, Soufras GD, Tsigkas G, Hahalis G. (2014). White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease. Clin Appl Thrombosis/ Hemostasis: Off J Int Acad Clin Appl Thrombosis/Hemostasis. [Epub ahead of print].
13. Koupenova M, Johnston-Cox H, Ravid K. (2012). Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors. Curr Atheroscler Rep 14:460-8.
14. Kushner FG, Hand M, Smith SC, et al. (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with STelevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54:2205-41.
15. Ledingham MA, Denison FC, Kelly RW, et al. (1999). Nitric oxide donors stimulate prostaglandin F(2alpha) and inhibit thromboxane B(2) production in the human cervix during the first trimester of pregnancy. Mol Hum Reprod 5:973-82.
16. Levine GN, Bates ER, Blankenship JC, et al. (2011). 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58: e44-122.
17. Linden MD, Jackson DE. (2010). Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 42:1762-6.
18. Mariano F, Bussolati B, Migliori M, et al. (2003). Platelet-activating factor synthesis by neutrophils, monocytes, and endothelial cells is modulated by nitric oxide production. Shock 19:339-44.
19. Mause SF, Ritzel E, Liehn EA, et al. (2010). Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. Circulation 122:495-506.
20. Mazereeuw G, Herrmann N, Bennett SA, et al. (2013). Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration. Neurosci Biobehav Rev 37:1611-21.
21. Mitsios JV, Vini MP, Stengel D, et al. (2006). Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol 26: 1907-13.
22. Nakahata N. (2008). Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118: 18-35.
23. Owens 3rd AP, Mackman N. (2011). Microparticles in hemostasis and thrombosis. Circ Res 108:1284-97.
24. Pernow J, Shemyakin A, Bohm F. (2012). New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91: 507-16.
25. Pfister SL. (2004). Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension 43:428-33.
26. Prokopi M, Pula G, Mayr U, et al. (2009). Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 114:723-32.
27. Ricevuti G, Mazzone A, De Servi S, et al. (1989). New trends in coronary artery disease: the role of granulocyte activation. Atherosclerosis 78:261-5.
28. Robert S, Poncelet P, Lacroix R, et al. (2009). Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost: JTH 7:190-7
29. Shantsila E, Kamphuisen PW, Lip GY. (2010). Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost: JTH 8:2358-68.
30. Siljander PR. (2011). Platelet-derived microparticles -an updated perspective. Thromb Res 127:S30-3.
31. Sinauridze EI, Kireev DA, Popenko NY, et al. (2007). Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97: 425-34.
32. Sonmez O, Ertas G, Bacaksiz A, et al. (2013). Relation of neutrophil-tolymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu kardiyoloji dergisi: AKD: Anatol J Cardiol 13:662-7.
33. Tao Wang, Daniel Palucci, Kelsey Law, et al. (2012). Atherosclerosis: pathogenesis and pathology. Diagn Mol Pathol 18:461-7.
34. Tonino PA, De Bruyne B, Pijls NH, et al. (2009). Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360:213-24.
35. Ueba T, Nomura S, Inami N, et al. (2010). Plasma level of plateletderived microparticles is associated with coronary heart disease risk score in healthy men. J Atheroscler Thromb 17:342-9.
36. van der Voort PH, van Hagen E, Hendrix G, et al. (1996). Comparison of intravenous adenosine to intracoronary papaverine for calculation of pressure-derived fractional flow reserve. Catheter Cardiovasc Diagn 39:120-5.
37. Velmurugan S, Kapil V, Ghosh SM, et al. (2013). Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med 65:1521-32.
38. Viera AJ, Mooberry M, Key NS. (2012). Microparticles in cardiovascular disease pathophysiology and outcomes. J Am Soc Hypertens: JASH 6:243-52.
39. Widmer A, Linka AZ, Attenhofer Jost CH, et al. (2003). Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology 99:25-31.
40. Xin Q, Keqiang L, Min W, et al. (2009). Relationship of platelet aggregation and inflammatory factors in patients with coronary heart disease. Chin Circ J 124:178-81.